Avelumab after chemotherapy for upper tract urothelial cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have upper tract urothelial cancer (cancer of the kidney or ureter) that has grown into the muscle or spread to lymph nodes, and you have already finished 3-4 rounds of cisplatin-based chemotherapy after surgery with no signs of cancer left.
- You are up and about (ECOG 0 or 1) and your blood counts, kidney function, and liver function are within certain limits.
- You have no active cancer spread, serious infections, autoimmune diseases requiring strong immune-suppressing drugs, or history of organ transplant.
- If you could become pregnant, you agree to use highly effective birth control during and for 30 days after the study drug.
- You have not had another cancer (except for cured ones), and you are willing to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial tests whether a maintenance drug called avelumab can help keep advanced bladder cancer from growing after you've completed two rounds of chemotherapy. It may help extend the time before the cancer returns.
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.